

A. IDENTIFICATION

Name: Sahar Saeed¹
Pronouns: She/Her
Email: sahar.saeed@queensu.ca
Website: www.saharsaeed.com
Affiliation: **Queen's University | Department of Public Health Sciences**

Phone: 1-514-945-0224
Citizenship: Canadian
Place of Birth: Toronto, Ontario

Languages: English (Native)
French: Spoken/written (Functional)
Farsi: Spoken (Functional)

Leave of absences: *Administrative Leave:* Sept 2020-2021 (*COVID-19 pandemic*)

Maternity Leaves, September 2010-2011 (Sarah); May 2012-2013 (Noah) research activities during these times were either suspended or significantly reduced

B. EDUCATION

2015-2019 **Ph.D. in Epidemiology**, McGill University, Montreal, Canada
CIHR Frederick Banting and Charles Best Canada Graduate Scholar
Dissertation: The Hepatitis C Treatment Revolution: Are Key HIV-Hepatitis C Co-Infected Populations Being Left Behind?
(*Fast tracked from MSc to PhD in 2015*)
Supervisors: Dr. Marina Klein & Dr. Erin Strumpf

2005- 2007 **M.Sc. in Human Genetics**, McGill University, Montreal, Canada
Dissertation: Fenretinide's Preventative Effect on the Development of Osteoporosis in Cystic Fibrosis
Supervisor: Dr. Danuta Radzioch

2002- 2005 **B.Sc. (Honors) in Biochemistry**, Carleton University, Ottawa, Canada
Honors thesis: Escape from non-self-recognition-associated self-incompatibility
Supervisor: Dr. Myron Smith

Post-Graduate:
2019-2022 **Post-Doctoral Scholar**, Washington University in St. Louis, USA
CIHR Postdoctoral Scholar
School of Medicine, Institute for Public Health, Center for Dissemination & Implementation
Supervisors: Dr. Elvin Geng (Washington University in St. Louis) & Dr. Maya Petersen (University of California-Berkeley)
Administrative Leave: Sept 2020-2021

¹ My name was legally changed from Zienab Saeed to Sahar Zienab Saeed (documentation available upon request)

C. APPOINTMENTS

2022- Assistant Professor (Tenure-Track), Department of Public Health Sciences
Queen's University
Kingston, Ontario

D. AWARDS, HONORS AND FELLOWSHIPS

SCHOLARSHIPS AND FELLOWSHIPS

2019-2022	CIHR Postdoctoral Fellowship Award Canadian Institute of Health Research <i>Ranked Top 10% Nationwide (Leave of Absence 09/2020-09/2021)</i>	\$150,000
2019-2021	Postdoctoral Fellowship Award Fonds de Recherche du Québec- Sante <i>Ranked second in Division, Province-wide (Declined as of 2020/9)</i>	\$110,000
2017-2020	Frederick Banting and Charles Best Canada Graduate Scholarship Canadian Institute of Health Research <i>Ranked Top 2.7%, Nationwide</i>	\$105,000
2016-2019	Doctoral Award Fonds de Recherche du Québec- Sante <i>Ranked first in Division, Province-wide (Declined as of 2017/5)</i>	\$60,000
2016-2019	Doctoral Award Canadian Hepatitis C Network <i>(Declined as of 2016/5)</i>	\$75,000
2015-2016	Graduate Research Enhancement and Travel awards (GREAT) Award McGill University <i>(Merit based, entering into the PhD program funded)</i>	\$3000
2014-2016	Masters Award National Hepatitis C Research and Training Program <i>(Declined as of 2015/9)</i>	\$35,700

PRIZES AND TRAVEL AWARDS

2021	Distinguished Abstract (Top 5%) American Association Blood Banks	
2021	Harold Gunson Fellowship International Society Blood Transfusion	
2020	Young Investigators Award 27th Conference on Retroviruses and Opportunistic Infection	\$1500 US
2019	Poster of Distinction 2019 Canadian Liver Meeting	

2018	Young Investigators Award 25th Conference on Retroviruses and Opportunistic Infection	\$1500 US
2018	Travel Award Canadian Institute of Health Research	\$2475
2018	GREAT Travel Award McGill Graduate and Postdoctoral Studies Office	\$1000
2017	Best Poster Second Infectious Diseases & Immunity in Global Health Research Day	\$200
2017	Poster of Distinction 2017 Canadian Liver Meeting	
2017	Travel Award Canadian Institute of Health Research	\$2449
2017	Travel Award Infectious Diseases and Immunity in Global Health McGill University Health Center	\$2000
2017	Young Investigators Award 24th Conference on Retroviruses and Opportunistic Infection	\$1500 US
2016	Best Presentation 5 th Canadian Symposium for Hepatitis C Research	\$500
2016	Second Prize Oral Presentation 11 th Epidemiology and Biostatistics Research Day	\$50
2015	Second Prize, Three-minute Thesis video University without Walls	\$500

E. RESEARCH FUNDING

2022-2023	Co-Investigator (PI: M. Klein) Project: After the Cure: Measuring the full impacts of direct acting antivirals for people living with HIV/hepatitis C virus coinfection in Canada CIHR Project Grant (Bridge Funding)	\$100,000
2022-2023	Co-Investigator (PI: Q. Nguyen) Project: Leveraging high-volume data to characterize age and individual-specific vital signs and to develop novel geriatric vital signs that optimally predict clinical outcomes in older adults CIHR Prize: Yves Joannette Award of Excellence in Research in Aging	\$50,000

2022-2025	Co-Investigator (PI: Q. Nguyen) Project: Leveraging high-volume data to characterize age and individual-specific vital signs and to develop novel geriatric vital signs that optimally predict clinical outcomes in older adults CIHR Project Grant (Ranked 1 st)	\$381,000
2020-2025	Co-Investigator (PI: G. Sebastiani) Project: The role of fatty liver in the epidemic of advanced chronic liver disease among people living with HIV CIHR Project Grant	\$685,440
2020-2021	Co-Investigator (PI: G. Sebastiani) Project: 1 st Workshop of the Canadian Non-Alcoholic SteatoHepatitis (CanNASH) Network CIHR Planning and Dissemination	\$10,000
2018-2019	Co-Investigator (PI: G. Sebastiani) Project: Association of vitamin D deficiency with severity of non-alcoholic steatohepatitis in HIV mono-infected patients CIHR-Canadian HIV Trials Network	\$50,000
2015-2016	Co-Investigator (PI: S. Segan) Project: 5 th Canadian Symposium on Hepatitis C Virus CIHR Planning and Dissemination	\$10,000
<i>Submitted</i>		
2022-2023	<i>Nominated Principal Applicant</i> <i>Project: Harnessing mobility for public health decision making</i> <i>CIHR Catalyst Grant</i>	\$100,000
2022-2023	<i>Co-Investigator</i> (PI: G. Sebastiani) <i>Project: Workshop of the Canadian Non-Alcoholic SteatoHepatitis (CanNASH) Network</i> <i>CIHR Planning and Dissemination</i>	\$10,000

F. INVITED PRESENTATIONS

Jun 2021	Seroprevalence in the vaccine era among blood donors, Public Health Agency of Canada & Blood Services
May 2021	Tracking SARS-CoV-2 seroprevalence among Canadian blood donors. Global Health Security Action Group (GHSAG) Lab Network which is comprised of G7+Mexico high containment labs, WHO and European Commission representatives. SARS-CoV-2 Seroprevalence: Navigating in the absence of a gold standard. Correlates of Immunity, Annual Stakeholders Meetings SARS-CoV-2 Seroprevalence Wave 2 Results. Public Health Agency of Canada & Blood Services

- Mar 2021 Tracking SARS-CoV-2 seroprevalence among Canadian blood donors. Physician's Biweekly Rounds. Canadian Blood Services
- Sept 2020 Tracking Mobility and COVID-19: Leveraging Big Data & Advanced Statistical Methods. Clinical Epidemiology Seminars. Jewish General Hospital, Montreal, Canada
- Mar 2020 An Interrupted Time Series Analysis to Evaluate the Impact of Differentiate Service Delivery in Zambia; Implementation Science Group, University of California, San Francisco, USA
- Apr 2019 Biological shocks and longitudinal analysis: Opportunities and Challenges
Longitudinal analysis methods for modelling the complexity of patient care;
Implementation Science Group, University of California, San Francisco, USA
- Mar 2019 The Hepatitis C Treatment Revolution: Are key HIV-HCV Co-infected populations being left behind? 15th Annual EBOH Research Day (Student Keynote) Montreal, Canada
- Feb 2019 Eliminating a Structural Barrier: Impact of Removing Fibrosis Stage Restrictions on HCV Treatment Uptake among People Living with HIV. Clinical Epidemiology Seminars. Jewish General Hospital, Montreal, Canada
- Feb 2016 & 2017 Epidemiology and Public Health of the Canadian Hepatitis C Symposium. CATIE Learning Institute. Banff, Canada
- Apr 2009 The Who, What, Where of Investigator Research, Young HIV Investigator Workshop, Canadian Association for HIV Research. Vancouver, Canada

G. TEACHING

COURSES:

Sept-Dec 2022

Health Services Research | EPID 837
Department of Public Health Sciences, Queen's University

This course will introduce research methods for evaluating outcomes and effectiveness of health care services using secondary data (with an emphasis on administrative databases). These methodologies are used to answer questions about which treatments, services and policies are effective when applied to whole populations in real practice and policy settings. In this course, students will learn the utility of using secondary data for research purposes and how to critically evaluate health services research studies. This will include the strengths and weaknesses of secondary databases, data accuracy, and bias. An emphasis will be made on various study designs and a variety of analytical methods to analyze the data based on the proposed research question. The course will have a strong focus on sources of secondary data available in Ontario.

Sept-Dec 2021&2018 **Fundamentals of Epidemiology | EPIB-601-2**
Department of Epidemiology and Biostatistics, McGill University

This course aims to provide a comprehensive introduction to modern epidemiologic concepts and methods. It is designed for graduate students with a variety of backgrounds and experience in public health. It covers, at the graduate level, fundamental concepts, principles, and methods of epidemiologic research and study design. Topics include measures of disease frequency and occurrence, measures of effect, study design, causality, bias and confounding, and interaction/effect measure modification. *Four credits*

2018 & 2021: Student evaluations were one-standard deviation above department average (available upon request)

Sept-Dec 2021 **Measurement in Epidemiology | EPIB-628**
Department of Epidemiology and Biostatistics, McGill University

Measuring health status is central to health research; this course examines the basic science of health measurement using scales and ratings. The advance course focuses on methodological issues related to measures of health and disease status encountered in clinical and epidemiological research. Topics include methodology and techniques of evaluating and improving health measurement-instruments and the critical evaluation of studies and papers on the properties of health measurement instruments. A focus is on latent variable models (principal components, confirmatory factor analysis, latent class models, item response theory, structural equation modelling).

2021: Student evaluations were above department average (available upon request)

LECTURES:

Jun 2022 Natural Experiments and Quasi-Experimental Study Designs, Clinical Epidemiology, Department of Epidemiology and Biostatistics, McGill University (2-hours)

Nov 2021 A Quasi-Experimental Approach: Using Difference-in-Differences, Principles of Study Design | EPIB 703, Department of Epidemiology and Biostatistics, McGill University (2-hours)

Nov 2019 A Quasi-Experimental Approach: Using Difference-in-Differences, Principles of Study Design | EPIB 703, Department of Epidemiology and Biostatistics, McGill University (2-hours)

Dec 2017 Understanding Biostatistics, Canadian Hepatitis C Webinar Series (1-hour)

Sept 2017 Effective Communications, Doctoral Seminar in Epidemiology | EPIB-706, Department of Epidemiology and Biostatistics, McGill University (1.5-hour)

2015-2018	Disease Detectives: Investigating Outbreaks Using Epidemiology. Canadian Medical Hall of Fame: Science Discovery Day. Montreal, Canada (8 x 2-hour interactive session; 30-35 high school students/session)
2017- 2019	Leader of Epidemiology Small Groups for Medical Student, McGill University (4 x 3-hour interactive session; 15-20 students/session) <i>Student Evaluation available upon request.</i>
May 2014	Food and Drug Regulations, Part C, Division 5 Health Canada Division, Clinical Research Solutions (2-hour lecture; 15-20 participants x 4 locations)
Sept 2011	Clinical Research Operations: The Importance of Standard Operating Procedures, Clinical Research Solutions (3-hour lecture; 15-20 participants x 4 locations)
May 2010	History of research ethics, Canadian Division 5 regulations and Introduction to Good Clinical Practice, Clinical Research Solutions (3-hour lecture, interactive exercise and exam; 15-20 participants x 10 locations)

H. SERVICE

2021	Peer reviewer , Canadian Institutes of Health Research (CIHR), Doctoral Research Awards – B peer review committee.
2020	Consultant to Dr. Quoc Dinh Nguyen, Head of Task Force focused on COVID-19 in Long-Term Care Facilities, for the Government of Quebec; Tasks included: epidemiological analysis of long-term care facilities, reviewing policy briefs, and rapid scientific reviews
2019	Co-Chair , Clinical Science Session, 8th Canadian Symposium on HCV Conference
2017	Member of Round Table Discussion, Career Advice, Young Investigators Workshop, Canadian Association for HIV Research,
2017	Student Representative of PhD Compensative exam committee, Department of Epidemiology, Biostatistics and Occupational Health, McGill University
2016	Member of Conference Organizing Committee, 5th Canadian Symposium on HCV Conference
2016	Co-Chair , Epidemiology and Public Health Session, 5th Canadian Symposium on HCV Conference
2015	Student Representative , Canadian Hepatitis C Network, Association, 2015/7 - Represent the trainees' interest (9 Post-Doctoral Fellows, 15 PhD and 2 MSc Students); Organize retreats at the annual meeting; Organize topics for journals clubs with administrator; Organize events for World Hepatitis Day; Develop materials for blog
2015	Founder , Critical Appraisal Journal Club, Club, recruited students and invited faculty to join; Selected articles/assigned topics; Led group discussions

- 2011 **Member** of organizing committee, 2nd Annual Young Investigators Workshop
Organizing Committee, Canadian Association of HIV Research
- 2010 **Founding member** of Young Investigators Workshop Organizing Committee,
Canadian Association of HIV Research

JOURNAL REVIEWER (AD HOC)

- 2015-present Addictions, BMJ Global Health, BMC Infectious Disease, Canadian Medical
Association Journal-Open, Canadian Liver Journal, International Journal of Drug
Policy, Journal of Clinical Epidemiology, Journal of Immigrant and Minority Health,
Journal of Viral Hepatitis, Journal of Preventative Medicine, PLOS-One

CONFERENCE ABSTRACT REVIEWER

- 2015-present 19th International Society for Pharmacoeconomics and Outcomes Research
(ISPOR) *European Congress*;
5th /6th /7th /8th/9th Canadian Symposium on HCV;
27th/28th/29th Canadian Conference on HIV/AIDS Research (CAHR);
8th/9th International Network on Hepatitis in Substance Users (INHSU);
52nd Annual Society for Epidemiological Research (SER)
13th Implementation and Dissemination Conference, Health Policy Dissemination &
Implementation track
American Association of Blood Banks

I. RESEARCH OVERVIEW

My research career began as a graduate student studying the pre-clinical effects of Fenretinide for the treatment of the ceramide deficiency present in patients with Cystic Fibrosis. My research led to six publications and the findings were instrumental in receiving the “Orphan Drug Designation” from the FDA in 2010, which have led to the completion of phase 1 and 2 clinical trials.

As part of my doctoral work, I made significant advances at uncovering barriers to treatment access among marginalized populations. I spearheaded projects to evaluate (1) the generalizability of clinical trials (2) describing the impact of patient-level barriers and system-level barriers on accessing treatments; and (3) evaluating the impact of treatments on health-related quality of life in real-world settings. My proficiency in quasi-experimental methodologies led me to write two tutorials designed to teach practitioners how to use these methods to answer public health and clinical questions broadly.

As a postdoctoral research fellow at Washington University Institute for Public Health, my research had local and global implications. The overarching rationale of my CIHR funded research is that in the modern era of HIV, factors associated with socioeconomic disparities and psychosocial comorbidities, would more accurately predict adverse HIV health outcomes compared to standard clinical predictors. Using machine learning methods, I planned to create an algorithm to predict people at high risk of disengaging from clinical care in the United States (*this research was put on hold*). Additionally, I engaged in global health research through the Centre for Infectious Disease Research in Zambia (CIDRZ) where I used quasi-experimental methodologies and evaluating the impact of differentiate service delivery on clinic volume, visit spacing and retention in care.

At the Canadian Blood Services, I applied my epidemiological training to evaluate SARS-CoV-2 seroprevalence among healthy blood donors, research that has been crucial at informing the COVID-19 Immunity Task Force. I championed to incorporate neighborhood-level census data to evaluate seroprevalence by socioeconomic factors, which revealed significant and growing disparities by material deprivation across Canada. While conducting an international scoping review, I highlighted the methodological challenges and offered solutions when conducting and analyzing seroprevalence studies among blood donors. I used a Bayesian Latent Class Model to demonstrate how using a single assay to estimate seroprevalence in a low prevalence setting was biased and how this bias could be corrected. Finally, now that we are in the era of highly efficacious and readily available vaccines, I was able to use results from multiple assays to distinguish natural infection and vaccine-induced humoral immunity to monitor waning antibody kinetics.

J. PUBLICATIONS

TOTAL CITATIONS= 1666 H-Index = 21 i10-INDEX=33

Underlined names highlight trainees; *Equal contribution; **Senior Author

Peer-Reviewed (48)

1. Her PH*, Saeed S*, Tram KH, Bhatnagar SR. Novel mobility index tracks COVID-19 transmission following stay-at-home orders. *Sci Rep* 2022. **12**, 7654
2. Laniece Delaunay C, Maheu-Giroux M, Marathe G, **Saeed S**, Martel-Laferriere V, Cooper C, Walmsley S, Cox J, Wong A, Klein MB. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. *Int J Drug Policy*. 2022. 103: 103627

3. Sebastiani G, Milic J, Cervo A, **Saeed S**, Krahn T, Kablawi D, Al Hinai AS, Lebouché B, Wong P, Deschenes M, Gioe C, Cascio A, Mazzola G, Guaraldi G. Two-tier care pathways for liver fibrosis associated to nonalcoholic fatty liver disease in HIV mono-infected patients. *J Pers Med*. 2022. 12(2): 282
4. **Saeed S**, Uzicanin S, Lewin A, Lieshout-Krikke R, Faddy H, Erikstrup E, Osiowy C, Steele WR, Davidson K, Custer B, O'Brien SF. Current challenges of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence studies among blood donors: A scoping review. *Vox Sang*. 2021. 1–12
5. Nguyen QD, Moodie EM, Desmarais P, Goulden R, Forget MF, Peters E, **Saeed S**, Keezer MR, Wolfson C. Appraising clinical applicability of studies: mapping and synthesis of current frameworks, and proposal of the FrACAS framework and VICORT checklist. *BMC Med Res Methodol*. 2021. 21(1): 248
6. **Saeed S**, O'Brien SF, Abe K, Yi Q, Rathod B, Wang J, Fazel-Zarandi M, Tuite A, Fisman D, Wood H, Colwill K, Gingras AC, Drews S. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard. *PLoS One*. 2021. 16(9): e0257743
7. Tram KH, **Saeed S**, Bradley C, Fox B, Eshun-Wilson I, Mody A, Geng E. Deliberation, Dissent, and Distrust: Understanding distinct drivers of COVID-19 vaccine hesitancy in the United States. *Clin Infect Dis*. 2021 Jul 16: ciab633. doi: 10.1093/cid/ciab633. Epub ahead of print
8. Altit G, **Saeed S**, Beltempo M, Claveau M, Lapointe A, Basso O. Outcomes of Extremely Premature Infants Comparing Patent Ductus Arteriosus Management Approaches. *J Pediatr*. 2021. 235: 49-57.e2
9. Palayew A, Schmidt AM, **Saeed S**, Cooper CL, Wong A, Martel-Laferrrière V, Walmsley S, Cox J, Klein MB; Canadian Coinfection Cohort Study Investigators. Estimating an individual-level deprivation index for HIV/HCV coinfecting persons in Canada. *PLoS One*. 2021. 16(4): e0249836
10. **Saeed S**, Goldman M, Uzicanin S, O'Brien. Evaluation of a Pre-exposure Prophylaxis (PrEP)/ Post Exposure Prophylaxis (PEP) Deferral Policy among Blood Donors. *Transfusion*. 2021. 61(6): 1684-1689
11. **Saeed S**, Drews SJ, Pambrun C, Qi-Long L, Osmond L, O'Brien SF. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. *Transfusion*. 2021. 61(3): 862-872
12. Lewin A, Drews SJ, Lieshout-Krikke R, Erikstrup E, **Saeed S**, Fady Helene, Steele WR, Uzicanin S, Custer B, O'Brien SF. An International Comparison of Anti-SARS-CoV-2 Assays used for seroprevalence surveys from blood Component Providers. *Vox Sang*. 2021. 115(9): 946-954
13. Laniece-Delaunay C, **Saeed S**, Nguyen Q. Evaluation of testing frequency and sampling for SARS-CoV-2 surveillance strategies in long-term care facilities. *J Am Med Dir Assoc*. 2020. 21(11): 1574–1576.e2.
14. Sebastiani G, **Saeed S**, LeBoucher B, de Pokomandy A, Szabo J, Haraoui LP, Routy JP, Wong P, Deschenes M, Ghali P, Klein MB, for the LIVEHIV Study Group. Vitamin E is an Effective Treatment for Non-alcoholic Steatohepatitis in HIV Mono-Infected Patients. *AIDS*. 2020. 34(2): 237-244
15. **Saeed S**, Strumpf EC, Moodie EE, Wong L, Cox J, Wong A, Walmsley S, Tyndall M, Cooper C, Conway B, Hull M, Martel-Laferrrière V, Gill J, Wong A, Vachon ML, Klein MB; Canadian Co-Infection Cohort Study. Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake among People Living with HIV. *Clin Inf Dis*. 2020. 71(2): 363-71
16. Cousineau SE, Eрман A, Liu L, **Saeed S**, Fradette L, Feld JJ, Grebly J, MacParland SA, Shoukry N, Sagan SM, on behalf of the Canadian Network on Hepatitis C (CanHepC). The 8th Canadian Symposium on Hepatitis C virus: “Improving diagnosis and linkage to care” *Canadian Liver Journal*. 2020. 3(1): 3-14

17. Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, Li Z, Pedrana A, Gottfredsson M, Bouscaillou J, Luhmann N, Mazhnaya A, Altice FL, **Saeed S**, Klein M, Falade-Nwulia O, Aspinall E, Hutchinson S, Hellard ME, Sacks-Davis R. Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs. *Liver Int.* 2019. 39(12): 2244-2260
18. **Saeed S**, Moodie EE Moodie, Strumpf E, Klein MB. Evaluating the Impact of Health Policies: Using a Difference-in-Differences Approach. *Int J Public Health.* 2019. 64(4):637-624
19. Nitulescu R, Young J, **Saeed S**, Cooper C, Cox J, Martel-Laferriere V, Hull M, Walmsley S, Tyndall MW, Wong A, Klein MB. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. *Int J Drug Policy.* 2019. 65:41-49
20. **Saeed S**, Moodie EEM, Strumpf EC, Gill MJ, Wong A, Cooper C, Walmsley S, Hull Mark, Martel-Laferriere V, Klein MB for the Canadian Co-Infection Cohort Study Investigators. Real-World Impact of Direct Acting Antiviral Therapy on Health-Related Quality of Life In HIV-Hepatitis C Co-Infected Individuals. *Journal of Viral Hepatitis.* 2018 25(12):1507-1514
21. Cheng ML, Abdel-Hakeem MS, Cousineau SE, Grebely J, Marshall AD, **Saeed S**, Sagan SM, Shoukry N, Feld JJ, MacParland SA, on behalf of the Canadian Network on Hepatitis C (CanHepC). The 7th Canadian Symposium on Hepatitis C Virus: “Toward Elimination of HCV: How to Get There” *Canadian Liver Journal* 2018 (3)139-152
22. Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, **Saeed S**, Lacombe K, Chkhartishvili N, Altice FL. Linkage and Retention in HCV Care For HIV-Infected Populations: Emerging Implementation Research. *Journal of the International AIDS Society* 2018 S2(21):e25051
23. Golizeh M, Melendex-Pena CE, Ward B, **Saeed S**, Santamaria C, Conway B, Cooper C, Klein MB, Ndao M on behalf of the Canadian Co-Infection Cohort (CTN 222). Proteomic Fingerprinting In HIV/HCV Co-Infection Reveals Serum Biomarkers for The Diagnosis of Fibrosis Staging. *PLOS One.* 2018 13(4): e0195148
24. **Saeed S**, Moodie EE Moodie, Strumpf E, Klein MB. Segmented Generalized Mixed Effect Models to Evaluate Health Outcomes. *International Journal of Public Health* 2018 63(4):547-551
25. Rossi C, **Saeed S**, Cox J, Vachon ML, Martel-Laferriere V, Walmsley S, Cooper C, Gill ML, Moodie EEM, Klein MB, for the Canadian Co-Infection Cohort Study. Hepatitis C Virus Cure Does Not Impact Kidney Function Decline in HIV Co-Infected Patients. *AIDS.* 2018; 32(6):751-759
26. **Saeed S**, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, Wong A, Walmsely S, Cooper C, Vachon ML, Martel-Laferriere V, Hull M, Conway B, Klein MB; Canadian Co-Infection Cohort Study. Disparities in Direct Acting Antivirals Uptake In HIV-Hepatitis C Co-Infected Populations in Canada. *Journal of the International AIDS Society.* 2017; 20(3)
27. Moqueet N, Kanagaratham C, Gill MJ, Hull M, Walmsley S, Radzioch D, **Saeed S**, Platt RW, Klein MB; Canadian Co-infection Cohort Study (CTN 222). A Prognostic Model for Development of Significant Liver Fibrosis In HIV-Hepatitis C Co-Infection. *PLoS One.* 2017;12(5): e0176282
28. **Saeed S**, Strumpf EC, Walmsley S, Rollet-Kurhajec K, Pick N, Martel-Laferriere V, Hull MW, Gill J, Cox J, Cooper C, Klein MB for the Canadian Co-Infection Cohort Study. How Generalizable are the Results

- from Trials of Direct Antiviral Agents to People Co-Infected With HIV/Hepatitis C Virus in The Real World? *Clinical Infectious Disease*. 2016; 62(7): 919-26
29. Marshall AD, **Saeed S**, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, Gallagher L, Klein MB, Shoukry NH, Taylor LE, Dore GJ, Grebely J, on behalf of the Canadian Network on Hepatitis C (CanHepC). Restrictions for Reimbursement of Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in Canada. *CMAJ Open* 2016 4(4): E604-E615
 30. van Buuren N, Fradette L, Grebely J, King A, Kraiden M, MacParland SA, Marshall A, **Saeed S**, Wilson J, Klein MB, Sagan S. The 5th Canadian Symposium on Hepatitis C Virus: We're Not Done Yet: Remaining Challenges in Hepatitis C. *Canadian Journal of Gastroenterology & Hepatology*. 2016:7603526
 31. Sagan SM, Dupont B, Grebely J, Kraiden M, MacParland SA, Raven JF, **Saeed S**, Feld JJ, Tyrrell DL, Wilson JA on behalf of the National CIHR Research Training Program in Hepatitis C. The Fourth Canadian Symposium on Hepatitis C: Moving Towards A National Action Plan. *Canadian Journal of Gastroenterology & Hepatology*. 2015: 5743521
 32. Kared H, **Saeed S**, Klein MB, Shoukry NH. CD127 Expression, Exhaustion Status and Antigen Specific Proliferation Predict Sustained Virologic Response to IFN in HCV/HIV Co-Infected Individuals. *PLoS One* 2014; Jul 9; 9(7) e101441
 33. Cox, J, Maurais E, Hu L, Moodie EEM, Law S, Bozinoff N, Potter M, Rollet K, Hull M, Tyndall M, Cooper C, Gill J, Saeed S, Klein MB, The Canadian Co-Infection Cohort (CTN 222) Correlates Of Drug Use Cessation Among Participants In The Canadian HIV-HCV Co-Infection Cohort. *Drug and Alcohol Dependence*. 2014 (137) 121-128
 34. Klein MB, Rollet K, **Saeed S**, Cox J, Potter M, Cohen J, Conway B, Cooper C, Côté P, Gill J, Haase D, Haider S, Hull M, Moodie E, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. HIV And Hepatitis C Virus Co-Infection In Canada: Challenges And Opportunities For Reducing Preventable Morbidity And Mortality. *HIV Medicine*. 2013; 14(1): 10-20
 35. Hull MW, Rollet K, Moodie EE, Walmsley S, Cox J, Potter M, Cooper C, Pick N, **Saeed S**, Klein MB; the Canadian Co-infection Cohort Study Investigators. Insulin Resistance Is Associated with Progression to Hepatic Fibrosis in a Cohort Of HIV/HCV Co-Infected Patients. *AIDS*. 2012; 10;26(14):1789-94
 36. Hull MW, Rollet K, Oduyungbo A, **Saeed S**, Potter M, Cox J, Cooper C, Gill J, Klein MB; Canadian Co-infection Cohort Investigators. Factors Associated with Discordance Between Absolute CD4 Cell Count and CD4 Cell Percentage in Patients Coinfected with HIV And Hepatitis C Virus. *Clinical Infectious Disease* 2012; 54(12):1798-805
 37. Thorpe J, **Saeed S**, Moodie EE, Klein MB, for the Canadian Co-infection Cohort Study. Interruption of Antiretroviral Therapy (ART) Is Associated with Progression of Liver Fibrosis In HIV/HCV Coinfected Adults. *AIDS*. 2011; 24;25(7):967-75
 38. Rizza SA, Cummins NW, Rider D, **Saeed S**, Klein MB, Badley AD. Polymorphism in TRAIL Receptor 1 is Associated with Poor Viral Response to Interferon Based HCV Therapy in HIV/HCV Co-Infected Individuals. *AIDS*. 2010; 13;24(17):2639-44
 39. Vali B, Jones RB, Sakhdari A, Sheth PM, Clayton K, Yue FY, Gyenes G, Wong D, Klein MB, **Saeed S**, Benko E, Kovacs C, Kaul R, Ostrowski MA. HCV-Specific T-cells in HCV/HIV Co-infection Show Elevated Frequencies of Dual Tim-3/PD-1 Expression that Correlate with Liver Disease Progression.

Eur J Immunol. 2010;40(9):2493-505

40. Potter M, Oduyungbo A, Yang H, **Saeed S**, Klein MB for the Canadian Co-infection Cohort Study Investigators. Impact of Hepatitis C Viral Replication on CD4+ T-Lymphocyte Progression In HIV-Co-Infection Before and After Antiretroviral Therapy. *AIDS*. 2010; 31;24(12):1857-66
41. Klein MB, **Saeed S**, Yang H, Cohen J, Conway B, Cooper C, Côté P, Cox J, Gill J, Haase D, Haider S, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. Cohort Profile: The Canadian HIV-Hepatitis C Co-Infection Cohort Study. *International Journal of Epidemiology*. 2010; 39(5):1162-9
42. Guilbault C, Wojewodka G, **Saeed Z**, Hajduch M, Matouk E, De Sanctis JB, Radzioch D. Cystic Fibrosis Fatty Acid Imbalance Is Linked to Ceramide Deficiency and Corrected by Fenretinide. *American Journal of Respiratory Cell and Molecular Biology* 2009;41(1):100-6
43. **Saeed Z**, Guilbault C, De Sanctis JB, Henri J, Marion D, St-Arnaud R, Radzioch D. Fenretinide Prevents the Development of Osteoporosis in Cftr-KO Mice. *Journal of Cystic Fibrosis* 2008;7(3):222-30
44. Wojewodka G, C Guilbault, **Saeed Z**, M Hajduch, E Matouk, JB De Sanctis, D Radzioch. Fenretinide Corrects Fatty Acid Imbalance in CF Mice: A Possible Therapy for CF Patients? *Journal of Cystic Fibrosis* 2008; 7(S28)
45. Guilbault C, De Sanctis JB, Wojewodka G, **Saeed Z**, Lachance C, Skinner TA, Vilela RM, Kubow S, Lands LC, Hajduch M, Matouk E, Radzioch D. Fenretinide Corrects Newly Found Ceramide Deficiency in Cystic Fibrosis. *American Journal of Respiratory Cell and Molecular biology* 2008;38(1):47-56
46. **Saeed Z**, Wojewodka G, Marion D, Guilbault C, Radzioch D. Novel Pharmaceutical Approaches for Treating Patients with Cystic Fibrosis. *Current Pharmaceutical Design* 2007;13(31):3252-63
47. Guilbault C, **Saeed Z**, Downey GP, Radzioch D. Cystic Fibrosis Mouse Models. *American Journal of Respiratory Cell and Molecular* 2007;36(1):1-7
48. Guilbault C, Novak JP, Martin P, Boghdady ML, **Saeed Z**, Guiot MC, Hudson TJ, Radzioch D. Distinct Pattern of Lung Gene Expression In The Cftr-KO Mice Developing Spontaneous Lung Disease Compared With Their Littermate Controls. *Physiological Genomics* 2006;25(2):179-93

Other Publications (1)

1. **Saeed S**, Lewin A, Lieshout-Krikke R, O'Brien SF. COVID-19: Blood Centers Rise to the Occasion and Lead Seroprevalence Studies. *Transfusion Today* (December 2020)

Under Review (1)

1. Shengir M, Elgretli W, Lebouche B, **Saeed S**, Ramanakumar AV, Giannakis A, De Pokomandy A, Cox J, Costiniuk C, Routy JP, Klein M, Sebastiani G. Changes in nonalcoholic fatty liver disease spectrum and metabolic markers in people living with HIV after switching to raltegravir-based regimen. Submitted to *AIDS*.

ABSTRACTS (95) (Oral/Poster noted when I was presenting author (n=36))

Underlined names highlight trainees; *Equal contribution; **Senior Author

1. Yokoji K, Regimbal-Athier A, Benomar K, **Saeed S****. The impact of the COVID-19 pandemic on profiles of STI testing and sexual behaviours among clients attending a STI self-testing clinic in Quebec: A Latent Class Analysis. *AIDS 2022 (Accepted)*
2. Shengir M, Elgretli W, Lebouche B, **Saeed S**, Ramanakumar AV, Giannakis A, De Pokomandy A, Cox J, Costiniuk C, Routy JP, Klein M, Sebastiani G. Changes in nonalcoholic fatty liver disease spectrum and metabolic markers in people with HIV after switching to a raltegravir-based regimen. *AIDS 2022 (Accepted)*
3. Soledad BC, **Saeed S**, Luu TM, Gorgos A, Beltempo M, Claveau M, Basso O, Lapointe A, Tremblay S, Altit G. Impact of a strict conservative PDA policy on neurodevelopmental outcomes – a difference-in-differences study. *CNPRM2022. (Accepted)*
4. **Saeed S**, O'Brien SF, Abe K, Yi Q, Tuite A, Fisman D, Wood H, Colwill K, Gingras AC, Drews S. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard. American Association for Blood Banks, October 2021 (**Awarded Best Abstract top 5%**)
5. **Saeed S**, Goldman M, Uzicanin S, O'Brien. Evaluation of a Pre-exposure Prophylaxis (PrEP)/ Post Exposure Prophylaxis (PEP) Deferral Policy among Blood Donors. American Association for Blood Banks, October 2021
6. **Saeed S**, Drews S, Pambrun C, Yi Q, Osmond L, O'Brien S. Tracking SARS-CoV-2 seroprevalence among Canadian blood donors through two pandemic waves. International Society for Blood Transfusion, June 2021 *Oral*
7. **Saeed S**, Uzicanin S, Lewin A, Lieshout-Krikke R, Erikstrup C, Seed C, Faddy H, Steele W, Custer B, O'Brien S. Current challenges of SARS-CoV-2 seroprevalence studies among blood donors: A scoping review. International Society for Blood Transfusion, June 2021 *Oral*
8. **Saeed S**, Uzicanin S, Lewin A, Drews SJ, Pambrun C, O'Brien S. Current challenges of SARS-CoV-2 seroprevalence studies among blood donors: A Scoping Review. Canadian Society for Transfusion Medicine Annual Conference. May 2021 *Oral*
9. **Saeed S**, Drews SJ, Pambrun C, Yi QL, Osmond L, O'Brien S. Tracking SARS-CoV-2 seroprevalence among Canadian blood donors. Canadian Society for Transfusion Medicine Annual Conference. May 2021 *Oral*
10. **Saeed S**, Goldman M, Uzicanin, O'Brien S. Impact of the COVID-19 pandemic on blood donations in Canada. Canadian Society for Transfusion Medicine Annual Conference. May 2021 *Oral*
11. Lanièce Delaunay C, Maheu-Giroux M, Marathe G, **Saeed S**, Cooper C, Walmsley S, Cox J, Hull M, Martel-Laferrrière, V Pick, N, Vachon M-L, Klein M. Are HIV-HCV coinfecting people who inject drugs accessing HCV prevention and care in Canada? Canadian Liver Meeting 2021 (CLM 2021, Virtual). May 2021
12. Lanièce Delaunay C, Maheu-Giroux M, Marathe G, **Saeed S**, Cooper C, Walmsley S, Cox J, Hull M, Martel-Laferrrière V, Pick N, Vachon ML, Klein MB. Temporal trends in access to hepatitis C virus

- (HCV) prevention and care among HIV-HCV coinfecting people who inject drugs in Canada. 30th Annual Canadian Conference on HIV/AIDS Research (CAHR 2021 Virtual), May 2021
13. **Saeed S**, Drews SJ, Pambrun C, O'Brien S. Waning anti-nucleocapsid IgG signal among SARS-CoV-2 seropositive blood donors: May- November 2020. 2021 Association of Medical Microbiology and Infectious Disease-Canada Conference. April 2021 *Oral*
 14. Lanièce Delaunay C, Maheu-Giroux M, Marathe G, **Saeed S**, Cooper C, Walmsley S, Cox J, Hull M, Martel-Laferrrière V, Klein MB. Access to HCV care among HIV-HCV coinfecting people who inject drugs across Canada. 28th Conference on Retroviruses and Opportunistic Infections (CROI 2021). March 6-10, 2021
 15. Tram KH, **Saeed S**, Mody A, Geng E. Socioeconomic status predicts local response to social distancing policies. AIDS 2020 (Virtual COVID-19 Special Conference)
 16. Laniece Delaunay C, Maheu-Giroux M, **Saeed S**, Cooper C, Cox J, Hull M, Martel-Laferrrière V, Moodie EEM, Vachon ML, Klein MB. Hepatitis C Virus (HCV) Treatment, Injection Practices, and Access to Harm Reduction among HIV-HCV co-infected People who Inject Drugs in Montréal from 2003-2018. 29th Annual Canadian Conference on HIV/AIDS Research (CAHR 2020), May 2020
 17. Palayew A, Schmidt A, **Saeed S**, Cooper C, Martel-Laferrrière V, Vachon ML, Hull M, Walmsley S, Klein MB. The validation of a novel deprivation index for co-infected individuals with non-attendance of a second visit. 29th Annual Canadian Conference on HIV/AIDS Research (CAHR 2020), May 2020
 18. Laniece Delaunay C, Maheu-Giroux M, **Saeed S**, Cooper C, Cox J, Hull M, Martel-Laferrrière V, Moodie EEM, Vachon ML, Klein MB. Hepatitis C Virus (HCV) Treatment, Injection Practices, and Access to Harm Reduction among HIVHCV co-infected People who Inject Drugs in Montréal from 2003-2018. Annual Student Research Day, McGill University, Department of Epidemiology, Biostatistics and Occupational Health, Montreal, March 2020.
 19. Cervo A, Krahn T, Milic J, **Saeed S**, Lebouché B, Klein M, Wong P, Deschenes M, Ghali P, Cascio A, Mazzola G, Guaraldi G, Sebastiani G. “Fib-4 First” Strategy in a NAFLD Pathway Assessment for HIV Monoinfected Patients. 27th Conference on Retroviruses and Opportunistic Infections (CROI 2020). March 2020, Boston, Massachusetts.
 20. **Saeed, S**, Moodie EMM, Walmsley S, Cooper C, Gill J, Wong A, Martel-Laferrrière V, Klein MB, for the Canadian Co-Infection Cohort Study. Treatment with Direct Acting Antivirals Reduces Healthcare Service Utilization. Conference on Retroviruses and Opportunistic Infections (CROI), March 2020, Boston, MA, USA. *Poster- Recipient of the Young Investigator's Award*
 21. Cervo A, Krahn T, Milic J, **Saeed S**, Lebouche B, Klein M, Wong P, Deschenes M, Ghali P, Cascio A, Mazzola G, Guaraldi G, Sebastiani G. “FIB-4 first” strategy in a NAFLD assessment pathway for HIV mono-infected patients. Canadian Liver Meeting, Montreal QC, February 2020.
 22. Altit G*, **Saeed S**, Claveau M, Beltempo M, Lapointe A, Basso O. Neonatal outcomes of extremely premature infants comparing patent ductus arteriosus management approaches. Sixth Annual Neonatal Cardiopulmonary Biology – Young Investigators Forum, September 2019, Chicago, IL, USA.
 23. **Saeed S**, Strumpf E, Moodie E, Cox J, Walmsley S, Cooper C, Conway B, Hull M, Barrett L, Martel-Laferrrière V, Tyndall M, Gill MJ, Klein MB for The Canadian Co-Infection Cohort Study. Eliminating a Structural Barrier: Impact of Removing Fibrosis Stage Restrictions on Hepatitis C Treatment Uptake among People Co-infected with HIV. Canadian Liver Meeting, May 2019, Montreal, Canada. *Poster with distinction*

24. Sebastiani G, **Saeed S**, De Pokomandy A, Lebouché B, Szabo J, Haraoui LP, Deschenes M, Wong P, Routy JP, Ghali P, Klein M. Vitamin E Is an Effective Treatment for NASH in people living with HIV: The CTN-PT 024 Trial. Canadian Liver Meeting, May 2019, Montreal, Canada.
25. Palayew A*, Schmidt AM, **Saeed S**, Cooper C, Martel-Lafferiere V, Klein MB. Estimation of an Individual-Level Deprivation index for HIV/HCV Co-infected Persons. 8th Canadian Symposium on Hepatitis C Virus, May 24, 2019, Montreal, Canada.
26. Palayew A*, Schmidt AM, **Saeed S**, Cooper C, Martel-Lafferiere V, Klein MB. Estimation of an Individual-Level Deprivation index for HIV/HCV Co-infected Persons. Canadian Liver Meeting, May 25-26, 2019, Montreal, Canada.
27. Jacka B, Klein M, Minoyan N, **Saeed S**, Rossi C, Zang G, Artenie AA, Jutras-Aswad D, Cooper C, Bruneau J. Recent sexual behaviour is not associated with HCV recurrent infection among men who inject drugs in Canada. 8th Canadian Symposium on Hepatitis C Virus, May 2019, Montreal, Canada
28. **Saeed S**, Strumpf E, Moodie E, Cox J, Walmsley S, Cooper C, Conway B, Hull M, Barrett L, Martel-Lafferiere V, Tyndall M, Gill MJ, Klein MB for The Canadian Co-Infection Cohort Study. Eliminating a Structural Barrier: Impact of Removing Fibrosis Stage Restrictions on Hepatitis C Treatment Uptake among People Co-infected with HIV. 8th Canadian Symposium on Hepatitis C Virus, May 2019, Montreal, Canada. *Poster*
29. **Saeed S**, Strumpf E, Moodie E, Cooper C, Barrett L, Cox J, Gill MJ, Hull M, Martel-Lafferiere V, Tyndall M, Walmsley S, Klein MB for The Canadian Co-Infection Cohort Study. Eliminating a Structural Barrier: Impact of Removing Fibrosis Stage Restrictions on HCV Treatment Uptake among People Living with HIV. 23rd International Workshop on HIV and Hepatitis C Observational Databases. March 2019, Athens, Greece *Poster*
30. Palayew A*, Schmidt AM, **Saeed S**, Cox J, Gill J, Walmsley S, Cooper C, Wong A, Pick N, Hull M, Klein MB, on behalf of the Canadian Co-infection Cohort. Estimation of an individual-level deprivation index for HIV/HCV co-infected persons in Canada and in four provinces. 28th Annual Canadian Conference on HIV/AIDS Research. 2019, Saskatoon, Canada.
31. Cocciolillo S, Osikowicz M, **Saeed S**, Deschenes M, Wong P, Ghali P, Lebouche B, Klein M, Sebastiani G. Vitamin E Is an Effective Treatment for Nash in HIV Mono-Infected Patients: The CTN-PT 024 Trial. Liver Meeting, American Association for the Study of Liver Diseases, November 2018, San Francisco, USA
32. **Saeed S**, Strumpf E, Moodie E, Cooper C, Barrett L, Cox J, Gill MJ, Hull M, Martel-Lafferiere V, Tyndall M, Walmsley S, Klein MB for The Canadian Co-Infection Cohort Study. Impact of Fibrosis Stage Restrictions on Hepatitis C (HCV) Treatment Initiation Rates: Overall and Among PWID in HIV-HCV Co-Infected Populations in Canada. 22nd International AIDS Conference, July 2018 Amsterdam, Netherlands *Poster*
33. **Saeed S**, Wong L, Cooper C, Wong A, Barrett L, Cohen J, Conway B, Côté P, Cox J, Gill MJ, Haider S, Hull M, Martel-Lafferiere V, Moodie EEM, Pick N, Rachlis A, Sadr A, Sanche S, Sandre R, Tyndall M, Vachon M-L, Walmsley S, Klein MB, for the Canadian Co-Infection Cohort Study. Is Hepatitis C Elimination Possible Among HIV-infected Population in Canada? 16th ISVHLD Global Hepatitis Summit. June 2018, Toronto, Canada *Oral*

34. **Saeed S**, Moodie EEM, Strumpf EC, Klein MB. Real World Impact Of Direct Acting Antiviral Therapy On Patient Reported Outcomes. Canadian Association for Health Services Research. May 2018, Montreal, Canada *Oral*
35. **Saeed S**, Moodie EEM, Hull M, Walmsley S, Cooper C, Wong A, Gill MJ, Martel-Laferriere V, Strumpf EC, Klein MB. Reductions in Healthcare Service Usage Following Direct Acting Antiviral Therapy. 3rd IDGIH. April 2018, Montreal, Canada *Poster*
36. **Saeed S**, Moodie EEM, Hull M, Walmsley S, Cooper C, Wong A, Gill MJ, Martel-Laferriere V, Strumpf EC, Klein MB. Reductions in Healthcare Service Usage Following Direct Acting Antiviral Therapy. 27th Canadian Association for HIV Research. April 2018, Vancouver, Canada *Poster*
37. **Saeed S**, Moodie EEM, Strumpf EC, Klein MB for the Canadian Co-Infection Cohort Study. Substance Use Following Direct Acting Antiviral Therapy: A Missed Opportunity? 27th Canadian Association for HIV Research. April 2018, Vancouver, Canada *Poster*
38. Rossi C, Young J, **Saeed S**, Wong L, Kronfli N, Klein MB. Low Rates of Failure of Direct-Acting Antiviral Therapies for Chronic Hepatitis C among HIV Co-Infected Canadians in a Real-World Clinical Setting. 27th Annual Canadian Conference on HIV/AIDS Research. April 2018, Vancouver, Canada
39. Nitulescu R, Young J, **Saeed S**, Cooper C, Cox J, Martel-Laferriere V, Hull M, Walmsley S, Tyndall M, Wong A, Klein MB, on behalf of the Canadian Co-infection Cohort. Variation in Hepatitis C Virus Treatment Uptake in the Era of Direct-acting Antivirals. 27th Annual Canadian Conference on HIV/AIDS Research. April 2018, Vancouver, Canada
40. **Saeed S**, Moodie EEM, Strumpf EC, Klein MB for the Canadian Co-Infection Cohort Study. Segmented Generalized Linear Mixed Models (GLMM) to Evaluate the Impact of Direct Acting Antiviral Therapy on Health Outcomes. 22nd International Workshop on HIV and Hepatitis C Observational Databases. March 2018, Malaga, Spain *Poster*
41. **Saeed S**, Moodie EEM, Strumpf EC, Klein MB for the Canadian Co-Infection Cohort Study. Substance Use Following Direct Acting Antiviral Therapy: A Missed Opportunity? 22nd International Workshop on HIV and Hepatitis C Observational Databases. March 2018, Malaga, Spain *Poster*
42. **Saeed S**, Moodie EEM, Strumpf EC, Klein MB. Reductions in Healthcare Service Usage Following Direct Acting Antiviral Therapy. 16th Annual Epidemiology and Biostatistics Student Research Day. March 2018 Montreal, Canada *Oral*
43. **Saeed S**, Moodie EEM, Hull M, Walmsley S, Cooper C, Wong A, Gill MJ, Martel-Laferriere V, Strumpf EC, Klein MB. Reductions in Healthcare Service Usage Following Direct Acting Antiviral Therapy. 25th Conference on Retroviruses and Opportunistic Infections (CROI), March 2018, Boston, MA, USA. *Poster- Recipient of the Young Investigator's Award*
44. **Saeed S**, Moodie EEM, Gill MJ, Wong A, Cooper C, Walmsley S, Hull Mark, Martel-Laferriere V, Strumpf EC, Klein MB. Real World Impact Of Direct Acting Antiviral Therapy On Patient Reported Outcomes. 7th Canadian Symposium on HCV, February 2018, Toronto, ON, Canada *Poster*
45. Rossi C, **Saeed S**, Klein MB. Low Rates of Failure of Direct-Acting Antiviral Therapies for Chronic Hepatitis C among HIV Co-Infected Canadians in a Real-World Clinical Setting. 7th Canadian Symposium on HCV, February 2018, Toronto, ON, Canada

46. **Saeed S**, Strumpf EC, Moodie E Klein MB, for the Canadian Co-Infection Cohort Study. Direct-acting antiviral initiation rates in vulnerable HIV-hepatitis C coinfecting populations in Canada: Can we reach elimination? 2nd IDIGH Research Day. April 2017 Montreal, Canada *Poster*
47. **Saeed S**, Strumpf EC, Walmsley S, Cooper C, Conway B, Martel-Laferriere V, Pick N, Wong A, Klein MB, for the Canadian Co-Infection Cohort Study. Direct acting antivirals uptake disparities in vulnerable HIV- Hepatitis C coinfecting populations in Canada. Canadian Association for HIV Research. April 2017 Montreal, Canada *Oral*
48. **Saeed S**, Strumpf EC, Moodie E Klein MB, for the Canadian Co-Infection Cohort Study. Direct-acting antiviral initiation rates in vulnerable HIV-hepatitis C coinfecting populations in Canada: Can we reach elimination? 21st International Workshop on HIV and Hepatitis C Observational Databases. March 2017 Lisbon, Portugal *Oral*
49. **Saeed S**, Strumpf EC, Walmsley S, Cooper C, Conway B, Martel-Laferriere V, Pick N, Wong A, Klein MB, for the Canadian Co-Infection Cohort Study. Direct Acting Antiviral Uptake Disparities in HIV-HCV Co-Infected Populations in Canada. 6th Canadian Symposium on Hepatitis C. March 2017, Banff, Canada. *Poster*
50. **Saeed S**, Strumpf EC, Walmsley S, Cooper C, Conway B, Martel-Laferriere V, Pick N, Wong A, Klein MB, for the Canadian Co-Infection Cohort Study. Direct Acting Antiviral Uptake Disparities in HIV-HCV Co-Infected Populations. Canadian Digestive Diseases Week 2017. March 2017, Banff, Canada. *Poster (with distinction)*
51. **Saeed S**, Strumpf EC, Walmsley S, Cooper C, Conway B, Martel-Laferriere V, Pick N, Wong A, Klein MB, for the Canadian Co-Infection Cohort Study. Direct Acting Antiviral Uptake Disparities in HIV-HCV Co-Infected Populations. 24th Conference On Retroviruses And Opportunistic Infections 2017 (CROI 2017), February 2017, Seattle, USA. *Poster-winner of the young investigator's award*
52. **Saeed S**, Strumpf E, Klein M. Who's getting Direct Acting Antivirals in a Canadian HIV/Hepatitis C Co-Infected Population. 12th Annual Student Day, Department of Epidemiology and Biostatistics April 2016, Montreal, Canada. *Poster*
53. **Saeed S**, Strumpf E, Klein M. Who's getting Direct Acting Antivirals in a Canadian HIV/Hepatitis C Co-Infected Population. Canadian Association for the Study of the Liver. February 2016, Montreal, Canada. *Poster*
54. **Saeed S**, Strumpf E, Klein M. Who's getting Direct Acting Antivirals in a Canadian HIV/Hepatitis C Co-Infected Population. 5th Canadian Symposium on Hepatitis C Virus. February 2016. Montreal, Canada. *Poster, Winner of best Clinical Science Presentation*
55. Moqueet N, Kanagaratham C, Radzioch D, **Saeed S**, Klein MB. Differential Immune Marker Levels Linked to Liver Fibrosis in HIV/Hepatitis C (HCV) Co-infection Canadian Association for the Study of the Liver. February 2016, Montreal, Canada. *Oral*
56. **Saeed S**, Rollet K, Strumpf E, Klein MB for the Canadian Co-Infection Cohort (CTN222). How generalizable are Direct Antiviral Agents (DAA) trials for real world people co-infected with HIV/Hepatitis C? International AIDS Society, July 2015, Vancouver, Canada *Oral*
57. **Saeed S**. How generalizable are Direct Antiviral Agents (DAA) trials for real world people co-infected with HIV/Hepatitis C? Student Day: Department of Epidemiology and Biostatistics April 2015, Montreal, Canada *Oral*

58. **Saeed S**, Strumpf E, Klein M. Evaluating the Impact of Direct Acting Antiviral's in HIV/Hepatitis C Co-Infected Individuals. 4th Canadian Symposium on Hepatitis C Virus. February 2015, Banff, Canada
Poster
59. Moqueet N, Kanagaratham C, Radzioch D, **Saeed S**, Klein MB. Differential Immune Marker Levels Linked to Liver Fibrosis in HIV/Hepatitis C (HCV) Co-infection. 21st Conference on Retroviruses and Opportunistic Infections. March 2014, Boston, USA
60. Melendez-Pena C, Habayeb M, **Saeed S**, Conway B, Cooper C, Ward B, Ndao M, Klein MB for the Canadian Co-Infection Cohort (CTN222). Serum biomarkers predictive of fibrosis by proteomic fingerprinting in HIV-1/HCV co-infection. 21st Annual Canadian Conference on HIV/AIDS Research. April 2012, Montreal, Canada
61. Klein MB, Rollet K, **Saeed S**, Moodie E, Cox J, Cooper C, Gill J, Hull M, Potter M, Walmsley S for the Canadian Co-Infection Cohort (CTN222). Who needs direct acting antivirals for hepatitis C virus (HCV)? Challenges faced in advancing HCV therapy with direct acting antivirals (DAAs) in HIV-HCV co-infected persons. 21st Annual Canadian Conference on HIV/AIDS Research. April 2012, Montreal, Canada
62. Klein MB, Rollet K, **Saeed S**, Cooper C, Conway B, Cox J, Gill J, Pick N, Potter M, Walmsley S for the Canadian Co-Infection Cohort (CTN222). Mortality in HIV-Hepatitis C virus (HCV) co-infected persons enrolled in the Canadian Co-infection Cohort study in comparison to the Canadian population. 21st Annual Canadian Conference on HIV/AIDS Research. April 2012, Montreal, Canada
63. Klein MB, Rollet KC, **Saeed S**, Cooper C, Conway B, Cox J, Gill J, Pick N, Potter M, Walmsley S for the Canadian Co-Infection Cohort (CTN222). Mortality in HIV-Hepatitis C (HCV) co-infected persons enrolled in the Canadian Co-infection Cohort Study in comparison to the Canadian population. 16th International Workshop on HIV Observational Databases. March 2012, Athens, Greece
64. Hull M, Yang H, Oduyungbo A, **Saeed S**, Montaner J, Klein MB for the Canadian Co-infection Cohort (CTN222). Factors associated with discordance between absolute CD4 cell count and CD4 percentage in HIV/Hepatitis C (HCV) co-infected patients. 7th International HIV and Hepatitis Co-infection Workshop. June 2011, Milan, Italy
65. Pick N, Rollet K, Burdge D, Fernandes E, Maan E, **Saeed S**, Klein MB, for the Canadian Co-infection Cohort (CTN222). Gender and liver disease progression in HIV Hepatitis C Virus (HCV) Co-infection. 20th Annual Canadian Conference on HIV/AIDS Research. Toronto, April 2011
66. Oduyungbo A, Lemire B, Wong A, Sicard C, Mousseau K, Sheehan NL, Perreault S, **Saeed S**, Moodie E, Klein MB and the Canadian Co-Infection Cohort Study (CTN222). Use of propensity score matching to adjust for baseline imbalance in longitudinal HIV databases: Association between male gender and progression of renal insufficiency among HIV patients. 20th Annual Canadian Conference on HIV/AIDS Research. April 2011, Toronto, Canada
67. Oduyungbo A, Lemire B, Wong A, Sicard C, Mousseau K, Sheehan NL, Perreault S, **Saeed S**, Moodie E, Klein MB and the Canadian Co-Infection Cohort Study (CTN222). Use of propensity score matching to adjust for baseline imbalance in longitudinal HIV databases: Association between male gender and progression of renal insufficiency among HIV patients. 15th International Workshop on HIV Observational Databases. March 2011, Prague

68. Lemire B, Wong A, Sicard C, Mousseau K, Oduyungbo A, Sheehan N, Perreault S, **Saeed S**, Klein MB: and the Canadian Co-infection Cohort Study (CTN222). Hepatitis C Co-Infection Leads to Greater Loss of Renal Function in HIV-Infected Patients. 18th Conference on Retroviruses and Opportunistic Infections. March 2011, Boston, USA
69. Habayeb M, Oduyungbo A, Rollet K, **Saeed S**, Walmsley S, Pick N, Conway B, Cox J, Hull M, Klein MB, and the Canadian Co-infection Cohort Study (CTN222). LDL Level as Prognostic Tool for Liver Disease Progression in HIV-Hepatitis C Virus (HCV) Co-Infection. 18th Conference on Retroviruses and Opportunistic Infections. March 2011, Boston, USA
70. Pick N, Castillo E, Rollet K, Burdge D, **Saeed S**, Klein MB, Canadian HIV-HCV Co-infection Cohort (CTN222). Gender and liver disease progression in HIV-hepatitis C co-infection. 1st International Workshop on HIV & Women. January 2011, Washington USA
71. Lemire B, Wong A, Sicard C, Mousseau K, Oduyungbo A, Sheehan N, Perreault S, **Saeed S**, Klein MB and the Canadian Co-infection Cohort (CTN222). La co-infection par l'hépatite C mène à une plus grande perte de fonction rénale chez les patients infectés par le VIH, La Journée des étudiants du FRSQ, November 2010, Montreal, Canada
72. Potter M, H Yang, **Saeed S**, J Cox, MB Klein for the Canadian Co-infection Cohort (CTN222). Obstacles to Hepatitis C Virus (HCV) Treatment Among HIV-HCV Co-infected Persons in Canada. XVIII International AIDS Conference, July 2010, Vienna, Austria
73. Cox J, Law S, Bozinoff N, Potter M, Oduyuo A, **Saeed S**, MB Klein for the Canadian Co-infection Cohort Study (CTN 222). Correlates of drug use cessation among participants in the Canadian HIV-HCV Co-infection Cohort (CCC): a step towards improving HCV therapy access. XVIII International AIDS Conference. July 2010, Vienna, Austria
74. Hull M, Yang H, Oduyuo A, **Saeed S**, J Montaner, MB Klein and the Canadian Co-infection Cohort Investigators (CTN222). Factors associated with discordance between absolute CD4 count and CD4 percentage in HIV/Hepatitis C (HCV) co-infected patients. 6th International HIV and Hepatitis Co-infection Workshop. June 2010, Tel Aviv, Israel
75. Thorpe J, **Saeed S**, Moodie EE, Klein MB, for the Canadian Co-infection Cohort Study. Interruption of Antiretroviral Therapy (ART) is Associated with Progression of Liver Fibrosis in HIV/HCV Co-infected Adults. 15th International Workshop on HIV Observational Databases. March 2010, Barcelona, Spain
76. Moodie EEM, **Saeed S**, Rouleau D, Cox J, Klein MB, for the Canadian Co-infection Cohort Study. Extending Marginal Structural Models for Competing Risks: The Effect ART Interruptions on Death. 15th International Workshop on HIV Observational Databases. March 2010, Barcelona, Spain.
77. Thorpe J, **Saeed S**, Moodie EE, Klein MB, for the Canadian Co-infection Cohort Study. Interruption of Antiretroviral Therapy (ART) is Associated with Progression of Liver Fibrosis in HIV/HCV Co-infected Adults. 19th Annual Canadian Conference on HIV/AIDS Research. May 2010, Saskatoon, Canada
78. Adams A, D Rouleau, J Cox, **Saeed S**, MB Klein for the Canadian Co-infection Cohort Study. Poor quality of life in HIV-Hepatitis C Virus (HCV) Co-infection is predominately a consequence of unfavourable social conditions. 19th Annual Canadian Conference on HIV/AIDS Research. May 2010, Saskatoon, Canada
79. Klein MB, J Thorpe, **Saeed S**, J Cohen, B Conway, C Cooper, P Côté, J Cox, J Gill, D Haase, S Haider, J Montaner, N Pick, A Rachlis, D Rouleau, R Sandre, M Tyndall, S Walmsley. A portrait of HIV-Hepatitis

- C co-infected persons in care in Canada: The Canadian Co-Infection Cohort Study (CCC; CTN 222). 19th Annual Canadian Conference on HIV/AIDS Research. May 2010, Saskatoon, Canada
80. Thorpe J, **Saeed S**, Moodie EE, Klein MB for the Canadian Co-Infection Cohort Study. Interruption of Antiretroviral Therapy (ART) is Associated with Progression of Liver Fibrosis in HIV/HCV Co-infected Adults. 17th Conference on Retroviruses and Opportunistic Infections, February 2010, San Francisco, USA
 81. Potter M, Yang H, **Saeed S**, Klein MB for the Canadian Co-Infection Cohort Study. Successful Hepatitis C Virus (HCV) Treatment Improves CD4⁺T lymphocyte Reconstitution in HIV/HCV Co-infected Adults. 17th Conference on Retroviruses and Opportunistic Infections, February 2010, San Francisco, USA
 82. Pant-Pai N, **Saeed S**, Lalonde R, Klein MB. In developed settings, do naïve HIV-1 Non-B subtypes respond and fail differently to first line HAART regimens? Results from a retrospective cohort study in Montreal. 5th Conference on HIV Pathogenesis and Treatment and Prevention. International AIDS Conference, Cape Town, July 2009.
 83. Fregonese F, Yang H, **Saeed S**, Klein MB, for the Canadian Co-Infection Cohort Study (CTN 222 cohort). Predictors of end stage liver disease (ESLD) in patients with HIV and HCV co-infection. 18th Annual Canadian Conference on HIV/AIDS Research, April 2009, Vancouver, Canada
 84. Potter M, Yang H, **Saeed S**, Klein MB for the Canadian Co-infection Cohort (CTN 222 cohort). Cocaine and crack use and resulting lifestyle instability are linked to a reduced access to Hepatitis C (HCV) treatments. 18th Annual Canadian Conference on HIV/AIDS Research, April 2009, Vancouver, Canada
 85. Potter M, Yang H, **Saeed S**, Klein MB for the Canadian Co-infection Cohort (CTN 222 cohort). First Nations Canadians have reduced access to Hepatitis C (HCV) treatment. 18th Annual Canadian Conference on HIV/AIDS Research, April 2009, Vancouver, Canada
 86. Klein MB, Potter M, Rouleau D, Cox J, Yang H, **Saeed S**, for the Canadian Co-infection Cohort (CTN 222 cohort). Excessive short-term mortality and causes of death in HIV and HCV co-infection: the importance of losses to follow-up. 18th Annual Canadian Conference on HIV/AIDS Research, April 2009, Vancouver, Canada
 87. Fregonese F, Yang H, **Saeed S**, Klein MB for the Canadian Co-Infection Cohort Study (CTN222). Predictors of end stage liver disease (ESLD) in patients with HIV and HCV co-infection. 13th International Workshop on HIV Observational Databases, Portugal, March 2009.
 88. Klein MB, DelBalso L, Carbonneau J, **Saeed S**, Yang H, Frosst E, Boivin G Viral pathogens including human metapneumovirus are the primary causes of febrile respiratory tract infection (RTI) in HIV-infected adults. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 2009, Montreal, Canada
 89. Potter M, Rouleau D, Cox J, Yang H, **Saeed S**, Klein MB. Effect of Spontaneous Clearance of Hepatitis C Virus on CD4 T-lymphocyte Counts in HIV/Hepatitis C Virus-co-infected Adults. 16th Conference on Retroviruses and Opportunistic Infections. February 2009, Montreal, Canada
 90. Wojewodka G, Guilbault C, **Saeed Z**, Hajduch M, Matouk E, De Sanctis JB, Radzioch D. Fenretinide corrects fatty acid imbalance in the mouse model of cystic fibrosis: possible therapy for CF patients? 31st Annual European Cystic Fibrosis Conference, June 2008, Prague, Czech Republic

91. Klein MB, Rouleau D, Cox J, **Saeed S**, Murphy T, Canadian Co-Infection Cohort Study. A detailed profile of HIV-Hepatitis C Virus (HCV) co-infected persons receiving care in Montreal: The Canadian HIV-Hepatitis C Cohort Pilot Study. 17th Annual Conference on HIV/AIDS Research, April 2008, Montreal, Canada
92. Pai NP, Murphy T, **Saeed ZS**, Lalonde RG, Klein MB. Does HIV-1 Clade Effect Duration of Initial Highly Active Antiretroviral Therapy (HAART)? 17th Annual Conference on HIV/AIDS Research, April 2008, Montreal, Canada
93. Klein MB, Rouleau D, Cox J, Lu Y, **Saeed S** and Canadian Co-Infection Cohort Study. Factors Associated with Hepatitis C virus (HCV) Treatment in a Prospective Cohort of HIV-HCV Co-Infected Persons. 12th International Workshop on HIV Observational Databases, March 2008, Malaga, Spain
94. Wojewodka G, C Guilbault, JB De Sanctis, **Z Saeed**, RM Vilela, S Kubow, L Lands, M Hajduch, E Matouk, D Radzioch. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis and improves P-aeruginosa clearance in CFTR-Ko mice, Pediatric Pulmonology, January 2007
95. Siahbazi M, **Saeed ZS**, Zymantas J, Gibbs C, Micali C, Wellman K and Smith ML. Escape from nonself recognition-associated self-incompatibility: genetic or epigenetic process? 3rd Annual Ottawa Carleton Institute of Biology, April 2006, Ottawa, Canada

K. RESEARCH IN MEDIA

- | | |
|------------|--|
| 2019/09/16 | Science Speaks: Global ID News,
https://sciencspeaksblog.org/2019/09/16/treatment-rationing-other-structural-barriers-stand-in-the-way-of-stopping-spread-of-hepatitis-c-among-people-living-with-hiv-study-finds/ |
| 2017/03/10 | Major Disparities Seen in Hep C Treatment Uptake Among Canadians With HIV,
www.poz.com/article/major-disparities-seen-hep-c-treatment-uptake-among-canadians-hiv |
| 2016/04/19 | Study Exclusions Raise Questions About HCV Treatment Results in People With HIV,
www.thebodypro.com/content/77459/study-exclusions-raise-questions-about-hcv-treatme.html |
| 2016/02/22 | For Those With HIV, Hep C Drug Trials Don't Offer Enough Real-World Data,
www.hepmag.com/article/hiv-hep-c-drug-trials-offer-enough-realworld-data |
| 2016/01/19 | Anti-HCV drugs interact with evening dosing of HIV-1 protease inhibitors
www.chronicliverdisease.org/reuters/article.cfm?article=20160119Scie1199584202&topic=scie |
| 2016/01/12 | How generalizable are the results from trials of Direct Antiviral Agents to people coinfectd with HIV/Hepatitis C virus in the real world?
www.mdlinx.com/infectious-disease/medical-news-article/2016/01/12/direct-acting-antivirals/6488304/ |

L. PROFESSIONAL RESEARCH EXPERIENCE

Epidemiologist (Contract)

Canadian Blood Services (CBS), Ottawa, ON

09/2020- 07/2021

- Led SARS-CoV-2 seroprevalence surveillance studies among healthy blood donors
- Independently spearheaded studies on COVID-19 and influenza vaccine coverage and hesitancy
- Provide expertise on policy and surveillance studies related transfusion transmissible infections

Accomplishments

- Stakeholder engagement with the Public Health Agency of Canada to promote using blood donors for surveillance studies
- Published four-peer reviewed manuscript
- Presented six oral presentations at three conferences (Association of Medical Microbiology and Infectious Disease; Canadian Society for Transfusion Medicine Annual Conference, and International Society for Blood Transfusion (ISBT).
 - Awarded the Harold Gunson Fellowship at the 2021 ISBT.
 - Awarded best abstract at the Canadian Society for Transfusion Medicine, leading to publication in *Transfusion Medicine Reviews*
 - Awarded best abstract at the American Association for Blood Banks

Epidemiologist

McGill University, Montreal, QC

09/2015- 07/2019

- Planned, designed and conducted complex epidemiological studies in the therapeutic areas of infectious and metabolic diseases (analyses included: survival analysis, mixed effect modelling, econometrics)
- Mentored students and staff providing guidance on study designs and statistical analysis

Accomplishments

- In addition to thesis-related work (six first-author high-impact original manuscripts) co-authored eleven other manuscripts during a period of four years
- Co-applicant on multiple government sponsored research grants (~\$750,000)

Co-founder and Consultant

Clinical Research Solutions, Montreal, QC

04/2012- 08/2017

- Led internal operations
 - Secured start-up funds, developed and executed business plan and infrastructure (including accounting) and marketing
 - Recruited and managed three associates
 - Designed, marketed and presented good clinical practice training workshops
- Consultant for academic investigators (therapeutic areas of HIV, Hepatitis C, Women's Health, Global Health and Cognition)
 - Prepared grant applications including budgets
 - Designed and implemented research protocols and case report forms (CRF)
 - Recruited and managed staff and external vendors
- Consultant for private medical clinic
 - Creation of a clinical research unit
 - On-site management of 16 pharmaceutical sponsored clinical trials and staff
 - Continuous quality assurance and Corrective and Preventative Actions (CAPA)
 - Trained young investigators (medical doctors)
 - Prepared Investigator-initiated protocols

Accomplishments

- Spearheaded a clinical database project focused on the individualization of patient care within the clinic. Secured funds through a clinical improvement program run by ViiV Healthcare (a subsidiary of GlaxoSmithKline) and led a multidisciplinary team to create a truly unique and valuable clinical tool that continues to monitor over 500 people living with HIV.
- Successfully supported academic-based endeavors such as creating a trauma registry at multiple hospitals in Mozambique. This project entailed coordinating a team of trauma surgeons who successfully were awarded a \$100,000 grant from Grand Challenges Canada.

Project Manager, Clinical Research**09/2009- 04/2012***Immunodeficiency Services, McGill University Health Center, Montreal, QC*

- Managed the operational execution of over 30 pharmaceutical sponsored clinical studies
- Prepared contingency plans and managed study start up, conduct, and closeout with respect to timelines
- Developed and implemented effective patient recruitment strategies
- Ensured all relevant studies follow ICH-GCP guidelines
- Oversaw preparation and submission of regulatory documents including submissions to the ethics committee and governmental agencies
- Reviewed and developed study budgets, contracts and book-keeping activities for the research unit (annual \$3 million budget)
- Served as single point of contact and source of consolidated information for the research unit (>30) including physicians, nurses, study coordinators, technicians, biostatisticians and analysts
- Managed all human resources

Research Associate**09/2009- 04/2012***Canadian HIV Trials Network, Vancouver, BC*

- Participated in the development and implementation of investigator-initiated protocols and randomized clinical trials in the Co-infections and Concurrent Diseases (CCD) Core

Accomplishments

- Assisted investigators obtain >\$5 million dollars of public funding through the Canadian Institute of Health Research
- Redesigned workflow to maximize recruitment

Clinical Research Coordinator**02/2007-09/2009***Canadian Co-Infection Cohort, McGill University Health Center, Montreal, QC*

- Coordinated all operational aspects of a multi-center clinical study in accordance with Good Clinical Practice (GCP) standards, internal regulatory requirements and standard operational procedures to ensure timely site initiations, subject enrollment, data monitoring, budget management and final reporting
- Supervised activities of 17 sites following 1200 patients across Canada
- Developed site feasibility questionnaires, case report forms, informed consent forms, participated in the development of the protocols and standard operating procedure
- Participated in study design for case-controlled studies, and longitudinal analysis
- Prepared and presented results at team meetings, investigator meetings, and conferences

Accomplishments

- Coauthor of nine manuscripts and twenty abstracts
- Assisted with multiple successful grant applications

Conference Coordinator

08/2007-04/2008

Canadian Association for HIV Research, Toronto, ON

- Organized a three-day national multi-disciplinary scientific conference on HIV research for more than 900 delegates
- Coordinated committee meetings, venue selections (conference and gala), scientific theme, plenary and keynote speakers, scientific program, workshops, commercial sponsors, continuing medical education (CME) accreditation, and the final report

Accomplishments

- Largest Canadian HIV conference to date
- Directed the volunteer program including recruitment and management of over 50 volunteers

M. ASSOCIATIONS

2015-	Society for Epidemiology Research
2015-	Canadian Association for Health Services and Policy Research
2014-	International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
2009-2018	Society for Clinical Research Associates (SoCRA)
2007-	Canadian Association of HIV/AIDS Research (CAHR)